These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 6952199)

  • 1. Inducer-mediated commitment of murine erythroleukemia cells to differentiation: a multistep process.
    Chen Z; Banks J; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):471-5. PubMed ID: 6952199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inducer-mediated commitment of murine erythroleukemia cells to terminal cell division: the expression of commitment.
    Murate T; Kaneda T; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1984 Jun; 81(11):3394-8. PubMed ID: 6203120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression during terminal differentiation: dexamethasone suppression of inducer-mediated alpha 1- and beta maj-globin gene expression.
    Kaneda T; Murate T; Sheffery M; Brown K; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1985 Aug; 82(15):5020-4. PubMed ID: 3860841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
    Marks PA; Michaeli J; Jackson J; Richon VM; Rifkind RA
    Prog Clin Biol Res; 1989; 316B():171-81. PubMed ID: 2616574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
    Ramsay RG; Ikeda K; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6849-53. PubMed ID: 3462732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.
    Michaeli J; Lebedev YB; Richon VM; Chen ZX; Marks PA; Rifkind RA
    Mol Cell Biol; 1990 Jul; 10(7):3535-40. PubMed ID: 1972544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of gene expression during terminal cell differentiation: murine erythroleukemia.
    Marks PA; Murate T; Kaneda T; Ravetch J; Rifkind RA
    Symp Fundam Cancer Res; 1984; 37():327-40. PubMed ID: 6084863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between globin mRNA accumulation and commitment to terminal cell differentiation in inducer sensitive and resistant erythroleukemia variants.
    Weich N; Marks PA; Rifkind RA
    Blood; 1990 Jul; 76(2):302-6. PubMed ID: 2369636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation.
    Melloni E; Pontremoli S; Damiani G; Viotti P; Weich N; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3835-9. PubMed ID: 3163801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
    Richon VM; Rifkind RA; Marks PA
    Cell Growth Differ; 1992 Jul; 3(7):413-20. PubMed ID: 1419904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in gene expression during hexamethylene bisacetamide induced erythroleukemia differentiation.
    Marks PA; Ramsay R; Sheffery M; Rifkind RA
    Prog Clin Biol Res; 1987; 251():253-68. PubMed ID: 3481077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.
    Marks PA; Rifkind RA
    Int J Cell Cloning; 1988 Jul; 6(4):230-40. PubMed ID: 3047266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic effect of butyrate on hexamethylene bisacetamide induced differentiation of murine erythroleukemia cells.
    Corin RE; Haspel HC; Peretz AM; Sonenberg M; Rifkind RA
    Cancer Res; 1986 Mar; 46(3):1136-41. PubMed ID: 3455880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythroleukemia cells: variants inducible for hemoglobin synthesis without commitment to terminal cell division.
    Marks PA; Chen Z; Banks J; Rifkind RA
    Proc Natl Acad Sci U S A; 1983 Apr; 80(8):2281-4. PubMed ID: 6572977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
    Kiyokawa H; Ngo L; Kurosaki T; Rifkind RA; Marks PA
    Cell Growth Differ; 1992 Jun; 3(6):377-83. PubMed ID: 1419901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of gene expression during terminal cell differentiation.
    Marks PA; Sheffery M; Rifkind RA
    Prog Clin Biol Res; 1985; 191():185-203. PubMed ID: 3901038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.
    Richon VM; Weich N; Leng L; Kiyokawa H; Ngo L; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1666-70. PubMed ID: 1672043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of alpha- and beta-globin messenger RNAs in mouse erythroleukemia cells.
    Nudel U; Salmon J; Fibach E; Terada M; Rifkind R; Marks PA; Bank A
    Cell; 1977 Oct; 12(2):463-9. PubMed ID: 912753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and conditions for selective expression of megakaryocytic markers in Friend erythroleukemia cells.
    Paoletti F; Vannucchi AM; Mocali A; Caporale R; Burstein SA
    Blood; 1995 Oct; 86(7):2624-31. PubMed ID: 7670106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.
    Richon VM; Ramsay RG; Rifkind RA; Marks PA
    Oncogene; 1989 Feb; 4(2):165-73. PubMed ID: 2648254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.